Travere Therapeutics is a biopharma focused on rare kidney diseases, with its lead drug FILSPARI approved for IgA nephropathy and focal segmental glomerulosclerosis, plus the older cystinuria treatment Thiola.
Revenue reached USD 0.49B in 2025, but the company is unprofitable with a net loss of USD 0.03B and a negative net margin of -5.21%, though losses have narrowed sharply from -76.70% in 2023.
FILSPARI's dual approvals for rare kidney diseases create a niche position, but competition from other rare-disease drugmakers and reliance on a single product limit durability.
Key events, in time order
Earnings data corroborated by analyst actions, though competition risks prompt downgrade
Post-Q2, analyst raises PT, reflecting confidence in Filspari growth
公司预计 FILSPARI 在 IgA 肾病和 FSGS 适应症中的总峰值销售额可能达到 30 亿美元。
None yet
None yet
TVTX is mentioned among stocks hitting 52-week highs, indicating strong upward momentum in the healthcare sector. The discussion focuses on recent price performance and potential valuation.
Main discussion
Stocks hitting fresh 52-week highs, highlighting strong momentum across technology, industrials, and healthcare, with PEG and P/S included to help assess growth and valuation. $WEX $PAYS $FLYW $RHI $MFP $MAN $GEO $CYRX $XNCR $TXG $TWST $TVTX $THC $PSNL $OGN $NEO $MRVI $MRK $IMMX
All these stocks hit new 52 WEEK HIGHS at some point today Merck $MRK Freeport-McMoRan $FCX Target $TGT BHP $BHP SSR Mining $SSRM Canadian Natural $CNQ 10x Genomics $TXG Virtu Financial $VIRT HF Sinclair $DINO Ovintiv $OVV Agilent Technologies $A Illumina $ILMN Becton Dickinson $
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
